Cancer metastasis: Molecular mechanisms and clinical perspectives

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 250, P. 108522 - 108522

Published: Sept. 1, 2023

Language: Английский

---

Therapeutic induction of antigen-specific immune tolerance

Nature reviews. Immunology, Journal Year: 2023, Volume and Issue: 24(5), P. 338 - 357

Published: Dec. 12, 2023

Language: Английский

---

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

MedComm, Journal Year: 2024, Volume and Issue: 5(9)

Published: Sept. 1, 2024

Abstract Cell death regulation is essential for tissue homeostasis and its dysregulation often underlies cancer development. Understanding the different pathways of cell can provide novel therapeutic strategies battling cancer. This review explores several key mechanisms apoptosis, necroptosis, autophagic death, ferroptosis, pyroptosis. The research gap addressed involves a thorough analysis how these be precisely targeted therapy, considering tumor heterogeneity adaptation. It delves into genetic epigenetic factors signaling cascades like phosphatidylinositol 3‐kinase/protein kinase B/mammalian target rapamycin (PI3K/AKT/mTOR) mitogen‐activated protein kinase/extracellular signal‐regulated (MAPK/ERK) pathways, which are critical death. Additionally, interaction microenvironment with cells, particularly influence hypoxia, nutrient deprivation, immune cellular interactions, explored. Emphasizing strategies, this highlights emerging modulators inducers such as B lymphoma 2 (BCL2) homology domain 3 (BH3) mimetics, tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL), chloroquine, innovative approaches to induce ferroptosis provides insights therapy's future direction, focusing on multifaceted circumvent drug resistance. examination evolving underlines considerable clinical potential continuous necessity in‐depth exploration within scientific domain.

Language: Английский

---

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 6, 2023

Abnormal cellular apoptosis plays a pivotal role in the pathogenesis of Multiple Myeloma (MM). Over years, BCL-2, crucial anti-apoptotic protein, has garnered significant attention MM therapeutic research. Venetoclax (VTC), small-molecule targeted agent, effectively inhibits promoting programmed death cancerous cells. While VTC been employed to treat various hematological malignancies, its particular efficacy showcased potential for broader clinical applications. In this review, we delve into intricacies how modulates cells by targeting BCL-2 and overarching influence protein family regulation. Our findings highlight nuanced interplay between VTC, MM, offering insights that may pave way optimizing strategies. Through comprehensive analysis, aim lay solid groundwork future explorations VTC’s applications profound effects on apoptosis.

Language: Английский

---

Apoptotic signaling: Beyond cell death

Seminars in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 156, P. 22 - 34

Published: Nov. 19, 2023

Language: Английский

---

Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on Polyploid/Senescent Giant Cancer Cells (PGCCs)

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(14), P. 11534 - 11534

Published: July 16, 2023

Single cell biology has revealed that solid tumors and tumor-derived lines typically contain subpopulations of cancer cells are readily distinguishable from the bulk by virtue their enormous size. Such with a highly enlarged nucleus, multiple nuclei, and/or micronuclei often referred to as polyploid giant (PGCCs), may exhibit features senescence. PGCCs enter dormant phase (active sleep) after they formed, but subset remain viable, secrete growth promoting factors, can give rise therapy resistant tumor repopulating progeny. Here we will briefly discuss prevalence prognostic value across different types, current understanding mechanisms formation fate, possible reasons why these “monsters” continue be ignored in most therapy-related preclinical studies. In addition PGCCs, other within (such oncogenic caspase 3-activated drug-tolerant persister cells) also contribute resistance pose major challenges delivery therapy.

Language: Английский

---

Acetyl-CoA metabolism as a therapeutic target for cancer

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 168, P. 115741 - 115741

Published: Oct. 19, 2023

Acetyl-coenzyme A (acetyl-CoA), an essential metabolite, not only takes part in numerous intracellular metabolic processes, powers the tricarboxylic acid cycle, serves as a key hub for biosynthesis of fatty acids and isoprenoids, but also signaling substrate acetylation reactions post-translational modification proteins, which is crucial epigenetic inheritance cells. Acetyl-CoA links lipid metabolism with histone to create more intricate regulatory system that affects growth, aggressiveness, drug resistance malignancies such glioblastoma, breast cancer, hepatocellular carcinoma. These fascinating advances knowledge acetyl-CoA during carcinogenesis normal physiology have raised interest regarding its modulation malignancies. In this review, we provide overview regulation cancer relevance main pathways participates. We summarize role reprogramming stress cells, well medical application inhibitors targeting dysregulation therapeutic intervention cancers.

Language: Английский

---

Cell death: Revisiting the roads to ruin

Developmental Cell, Journal Year: 2024, Volume and Issue: 59(19), P. 2523 - 2531

Published: Oct. 1, 2024

A paradigm shift in the study of cell death is currently occurring: whereas previously we had always considered that there were "points no return" any pathway, now realize many types active, regulated death, this not case. We are also learning cells "almost die," but nevertheless survive, can transiently take on an altered state, with potential implications for understanding cancer therapies and relapse. In perspective, parse forms by analogy to suicide, sabotage, murder, consider how might be "instructed" engage a pathway survive.

Language: Английский

---

Sublethal engagement of apoptotic pathways in residual cancer

Trends in Cell Biology, Journal Year: 2023, Volume and Issue: 34(3), P. 225 - 238

Published: Aug. 10, 2023

Language: Английский

---

Polyploid Giant Cancer Cells Generated from Human Cytomegalovirus-Infected Prostate Epithelial Cells

Cancers, Journal Year: 2023, Volume and Issue: 15(20), P. 4994 - 4994

Published: Oct. 15, 2023

Prostate cancer is the most commonly diagnosed malignancy and sixth leading cause of death in men worldwide. Chromosomal instability (CIN) polyploid giant cells (PGCCs) have been considered predominant hallmarks cancer. Recent clinical studies proven association CIN, aneuploidy, PGCCs with poor prognosis prostate (PCa). Evidence HCMV transforming potential might indicate that may be involved PCa.Herein, we underline role high-risk HCMV-DB -BL strains epithelial assess molecular cellular oncogenic processes associated PCa.Oncogenesis parallels a sustained growth "CMV-Transformed cells" or CTP highly express Myc EZH2, forming soft agar colonies displaying stemness as well mesenchymal features, hence promoting EMT spheroid appearance.HCMV-induced EZH2 upregulation coupled traits IE1-expressing highlight PCa development encourage use anti-EZH2 anti-HCMV treatment.

Language: Английский

---